InMed Pharmaceuticals Inc. $INM

By Microcap Ledger desk · CIK 0001728328

Facts as of Oct 11, 2026, 08:18 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Vancouver
Fiscal year end: June 30
Shares outstanding: 5,493,735 [10-K 2026-09-09]
as of 2026-09-02

Sources: [10-K 2026-09-09]

What the company doesAI summary of filing

InMed Pharmaceuticals is a pharmaceutical development company with a pipeline of small molecule drug candidates targeting CB1 and CB2 receptors in the endocannabinoid system. The company is currently pre-revenue and clinical-stage, having wound down its only revenue-generating commercial operations segment (BayMedica) as of June 2026. The company is developing three drug candidates: INM-901 for Alzheimer's disease (in preclinical stage with a planned Phase 1 trial targeted for 2027), INM-089 for dry age-related macular degeneration (in preclinical development), and INM-755 (cannabinol) cream for epidermolysis bullosa (completed Phase 2 clinical trial). InMed's remaining development activities require additional financing, which is not assured. [10-K 2026-09-09]

Segments: INM-901 (Alzheimer's disease), INM-089 (dry AMD), INM-755 (epidermolysis bullosa)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
FY ended Jun 2026	—	−$12.56M	−$8.64M	$2.19M	[S-4/A 2026-09-29]
FY ended Jun 2025	$4.94M	−$8.16M	−$8.10M	$10.74M	[S-4 2026-07-02]

Quarterly cash burn: −$2.16M
Cash runway Estimate: ~3 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-14	718,032	[10-Q 2024-11-14]
2025-02-07	1,207,186	[10-Q 2025-02-12]
2025-05-09	1,207,186	[10-Q 2025-05-12]
2025-09-17	2,384,186	[10-K/A 2025-10-24]
2025-10-31	2,804,186	[10-Q 2025-11-06]
2026-02-09	2,919,186	[10-Q 2026-02-11]
2026-05-04	3,314,063	[10-Q 2026-05-06]
2026-09-02	5,493,735	[10-K 2026-09-09]

Shelf registration: S-3 filed 2026-03-20; declared effective 2026-03-30 [S-3 2026-03-20]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-09-18	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-09-18]
2026-03-30	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-03-30]
2024-11-05	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2024-11-05]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-10-08	Adar1 Capital Management, Llc	buy	2,256	$1.33	[4 2026-10-08]
2026-10-07	Adar1 Capital Management, Llc	buy	3,046	$1.33	[4 2026-10-08]
2026-10-06	Adar1 Capital Management, Llc	buy	5,601	$1.33	[4 2026-10-08]
2026-10-05	Adar1 Capital Management, Llc	buy	18,182	$1.33	[4 2026-10-05]
2026-10-02	Adar1 Capital Management, Llc	buy	8,307	$1.33	[4 2026-10-05]
2026-10-01	Adar1 Capital Management, Llc	buy	16,431	$1.33	[4 2026-10-05]
2026-09-16	Adar1 Capital Management, Llc	buy	8,340	$1.29	[4 2026-09-16]
2026-09-15	Adar1 Capital Management, Llc	buy	54,256	$1.30	[4 2026-09-16]
2026-09-14	Adar1 Capital Management, Llc	buy	28,505	$1.29	[4 2026-09-16]
2026-07-16	Vivo Opportunity, Llc	buy	19	$1.55	[4 2026-07-16]
2026-07-16	Vivo Opportunity, Llc	buy	2	$1.55	[4 2026-07-16]
2026-07-15	Adar1 Capital Management, Llc	buy	1,000	$1.55	[4 2026-07-17]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-07	13G/A	Beneficial ownership report (5%+ holder)
2026-10-01	424B3	Prospectus or prospectus supplement
2026-09-18	8-K	Listing notice or transfer; Other events
2026-09-09	10-K	Annual report
2026-08-14	13G	Beneficial ownership report (5%+ holder)
2026-07-22	8-K	Regulation FD disclosure; Other events
2026-07-10	8-K	Material agreement entered; Regulation FD disclosure
2026-06-10	13D	Beneficial ownership report (5%+ holder)
2026-06-10	8-K	Other events
2026-06-05	13G	Beneficial ownership report (5%+ holder)
2026-05-27	13G	Beneficial ownership report (5%+ holder)
2026-05-19	8-K	Material agreement entered; Change in control; Director or officer change

Facts as of Oct 11, 2026, 08:18 AM UTC. Small caps move fast; check the latest filings.